Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...

The hub will evaluate how emerging therapeutics, including GLP-1 agonists, might impact cancer progression and treatment.

Cancer screening tests can be divided into early detection and preventive tests.1 Early-detection tests (eg, mammography for ...

Ending clinical trials with no warning can put patients at risk.

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...